Hikmat Al‐Ahmadie

Memorial Sloan Kettering Cancer Center

Full Professor(heuristic)

Bladder and Urothelial Cancer Treatments · Surgery

h-index106

i10-index282

Publications814

Citations89,585

Grants

16 total · 0 active

NIH #5P50CA221745-05

Biospecimen Repository Core

Amount: $200K
Period: 2018-08-24 → 2025-07-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #3P50CA221745-05S1

Biospecimen Repository Core

Amount: $129K
Period: 2018-08-24 → 2025-07-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #5P01CA221757-05

Core A: Molecular Pathology Core

Amount: $310K
Period: 2018-09-11 → 2024-08-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at COLUMBIA UNIVERSITY HEALTH SCIENCES

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 84

Supplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026-06-17
Supplemental Figures from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026-06-17
Supplementary Sequencing Data1 from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer
2026-06-17
Supplementary tables/figures1 from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer
2026-06-17
Table S1 from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026-06-17
Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026-06-17
Data from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer
2026-06-17
Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models
The Journal of Experimental Medicine · 2026-04-29
Neuroendocrine tumours of the urinary bladder: recent advances
Histopathology · 2025-12-12
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
2025-11-25
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
2025-11-25
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
2025-11-25
Intratumoral early activated TCF1+ CD4 Th cells drive effector CD8 T cell responses in a novel sarcomatoid RCC model through anti-CTLA4 therapy 3951
The Journal of Immunology · 2025-11-01
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum
The Journal of Urology · 2025-10-09
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort
European Urology · 2025-09-27 · 6 citations
Abstract B098: Global-scale patient-partnered genomic databanking: unlocking therapeutic and biological insights in rare cancers through decentralized recruitment and open data sharing
Cancer Epidemiology Biomarkers & Prevention · 2025-09-18
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
Journal of Clinical Oncology · 2025-09-11 · 14 citations
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
Nature Communications · 2025-09-10 · 7 citations
Machine Learning Using >300,000 H&E Images Refines Cancer of Unknown Primary Subtyping
International Journal of Radiation Oncology*Biology*Physics · 2025-09-01
3089P Clinical outcomes with enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma and divergent differentiation or histologic subtypes
Annals of Oncology · 2025-09-01

Open author page on OpenAlex →

Hikmat Al‐Ahmadie

Grants

Biospecimen Repository Core

Biospecimen Repository Core

Core A: Molecular Pathology Core

All Grants

Biospecimen Repository Core

Biospecimen Repository Core

Core A: Molecular Pathology Core

Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

Core A: Molecular Pathology Core

Biospecimen Repository Core

Biospecimen Repository Core

Core A: Molecular Pathology Core

Biospecimen Repository Core

Core A: Molecular Pathology Core

Core A: Molecular Pathology Core

Biospecimen Repository Core

Career Trajectory

Research Cluster Map

Potential Collaborators

Recent Publications